Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, was introduced to regulate therapeutic goods in Australia, ensuring they meet safety, quality, and efficacy standards. The legislation provides the framework for the regulation of therapeutic goods, including medicines, medical devices, and blood products, to protect public health. The Act aims to safeguard the health and safety of the Australian population by ensuring that only therapeutic goods that meet the required standards are available for supply within the country. The legislation was enacted to address the need for a comprehensive regulatory system that could manage the importation and supply of therapeutic goods, ensuring that these products are safe and effective for use. This legislative instrument, under subsection 19A(3) of the Therapeutic Goods Act 1989, specifies certain countries whose approval for general marketing is a prerequisite for the importation or supply of specified therapeutic goods in Australia. The determination was made by Jane Halton, the Secretary to the Department of Health and Ageing, on the 5th of May 2004. The listed countries include the United Kingdom, Sweden, the United States of America, Germany, the Netherlands, Canada, Switzerland, France, and New Zealand. This determination highlights the importance of international collaboration and regulatory alignment in maintaining public health standards and ensuring the safety of therapeutic goods entering Australia.

Scope and Application

The Therapeutic Goods Act 1989, as supplemented by the 2004 legislative instrument, applies to the importation and supply of specified therapeutic goods into Australia. It mandates that certain therapeutic goods originating from a list of specified foreign countries—namely the United Kingdom, Sweden, the United States of America, Germany, the Netherlands, Canada, Switzerland, France, and New Zealand—must have undergone registration or approval for general marketing in their respective countries before they can be imported or supplied in Australia. This requirement is enforced by the Secretary to the Department of Health and Ageing, who exercises their powers under subsection 19A(1) of the Act. The legislation does not specify any exclusions or exemptions, but its application can be extended or restricted through subordinate instruments. The Act operates on a national level, applying across all states and territories within Australia, ensuring a unified regulatory approach to the therapeutic goods market.

Key Provisions

The Therapeutic Goods Act 1989 (sections 19A(1) and 19A(3)) mandates that certain therapeutic goods must be registered or approved for general marketing in specified foreign countries before they can be imported or supplied in Australia. In this context, the Secretary to the Department of Health and Ageing has specified particular countries where this registration or approval is required. The countries listed are the United Kingdom, Sweden, the United States of America, Germany, the Netherlands, Canada, Switzerland, France, and New Zealand. This legislative instrument aims to ensure that the therapeutic goods entering Australia meet the required standards of safety, quality, and efficacy as determined by these foreign regulatory authorities. The Act imposes obligations on entities seeking to import or supply specified therapeutic goods in Australia. It mandates that these goods must have undergone a registration or approval process in one of the listed countries before they can be brought into Australia. This requirement is pivotal in maintaining a robust framework for the regulation of therapeutic goods, ensuring that only those goods that meet stringent international standards are available to the Australian public. Importers and suppliers must therefore verify that the therapeutic goods they intend to bring into Australia have the necessary approvals from the specified countries. This verification process is crucial to comply with the Act and avoid legal repercussions. Failure to comply with the requirements of the Therapeutic Goods Act 1989 can result in serious legal consequences. Any person or entity that imports or supplies therapeutic goods without the necessary registration or approval from the specified countries may face civil or criminal penalties. The Act does not specify maximum penalties within the text of this determination, but generally, penalties for breaches can include substantial fines, imprisonment, or both, depending on the severity of the offence. These measures are intended to deter non-compliance and to ensure that the health and safety of Australian consumers are protected by only allowing therapeutic goods that meet international standards to be marketed in Australia.